Marine Drugs (Jan 2023)

A Survey of Didemnin Depsipeptide Production in <em>Tistrella</em>

  • Robert J. Stankey,
  • Don Johnson,
  • Brendan M. Duggan,
  • David A. Mead,
  • James J. La Clair

DOI
https://doi.org/10.3390/md21020056
Journal volume & issue
Vol. 21, no. 2
p. 56

Abstract

Read online

As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family Didemnidae, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria Tistrella mobilis. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in Tistrella currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of Tistrella and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.

Keywords